Alina N. Egorova

R-Pharm (Russia) — Russia

Medicine · Health Sciences

8h-index529citations17works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

COVID-19 Clinical Research Studies(5), SARS-CoV-2 and COVID-19 Research(4), Rheumatoid Arthritis Research and Therapies(2), Health disparities and outcomes(2), Acute Myocardial Infarction Research(2)

Publications17 total

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period
Pharmaceuticals·2025Open Access
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial
Arthritis Research & Therapy·2025Open Access
Abstract 4340531: Interleukin-1 Blockade in Patients With ST-Segment-Elevation Myocardial Infarction: a Pooled Analysis of Randomized Clinical Trials of Anakinra and Goflikicept
Circulation·2025
Long-term goflkicept therapy for patients with idiopathic recurrent pericarditis: results of the interim analysis of an ongoing open-label extension study
Terapevticheskii arkhiv·2024· 1 citedOpen Access
Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study
Journal of Cardiovascular Pharmacology·2024· 11 citedOpen Access
Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment–Elevation Myocardial Infarction (STEMI)
Circulation·2024· 19 cited
Results of a 24-week open-label phase II study of olokizumab in adolescent patients with polyarticular juvenile idiopathic arthritis
Voprosy praktičeskoj pediatrii·2024· 1 cited
Tobacco, Alcohol and Diet as Mortality Risk Factors: the secondary analysis of the 25-year Cohort Study
Journal of Health Research·2023· 1 citedOpen Access
Treatment of Idiopathic Recurrent Pericarditis With Goflikicept
Journal of the American College of Cardiology·2023· 60 cited
Cohort profile: The longitudinal study on the risk factors of non-communicable diseases in Russia
Vestnik of Saint Petersburg University Medicine·2022Open Access
Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study
Journal of Psychiatric Research·2021· 11 cited
Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients
Viruses·2021· 12 citedOpen Access
Апротинин — эффективный мультитаргетный препарат для комбинированной терапии новой коронавирусной инфекции COVID-19 средней степени тяжести
2020Open Access
Aprotinin is a potent multi-target drug for the combination therapy of moderate COVID-19 cases
2020· 1 citedOpen Access
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Clinical Infectious Diseases·2020· 258 citedOpen Access
Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19
2020· 20 citedOpen Access
Outer membrane vesicles secreted by pathogenic and nonpathogenic Bacteroides fragilis represent different metabolic activities
Scientific Reports·2017· 133 citedOpen Access

Frequent Co-authors

Andrey A. Ivashchenko(6), Рубен Карапетян(6), Elena A. Merkulova(6), Samsonov MIu(6), E. N. Simakina(5), Alexandre V. Ivachtchenko(5), Dmitry V. Kravchenko(4), Nikolay Savchuk(4), Elena V. Yakubova(4), Antonio Abbate(4), Еkaterina G. Ponomar(4), Sergey Grishin(4), Natalia Vostokova(3), Valeria N. Azarova(3), Yan Lavrovsky(3), Benjamín Van Tassell(3), Roshanak Markley(3), Paul Cremer(3), I. Meray(3), Dmitry V. Privalov(3)